Terms: = Prostate cancer AND REL, I-Rel, 5966, ENSG00000162924, C-Rel AND Treatment
11 results:
1. Inducing apoptosis by using microRNA in radio-resistant prostate cancer: an in-silico study with an in-vitro validation.
Darvish L; Bahreyni-Toossi MT; Aghaee-Bakhtiari SH; Firouzjaei AA; Amraee A; Tarighatnia A; Azimian H
Mol Biol Rep; 2023 Jul; 50(7):6063-6074. PubMed ID: 37294470
[TBL] [Abstract] [Full Text] [Related]
2. relA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract] [Full Text] [Related]
3. Regulation of mRNA gene expression of members of the NF-κB transcription factor gene family by angiotensin II and relaxin 2 in normal and cancer prostate cell lines.
Domińska K; Kowalska K; Matysiak ZE; Płuciennik E; Ochędalski T; Piastowska-Ciesielska AW
Mol Med Rep; 2017 Jun; 15(6):4352-4359. PubMed ID: 28487955
[TBL] [Abstract] [Full Text] [Related]
4. Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Pelzer U; Blanc JF; Melisi D; Cubillo A; Von Hoff DD; Wang-Gillam A; Chen LT; Siveke JT; Wan Y; Solem CT; Botteman MF; Yang Y; de Jong FA; Hubner RA
Br J Cancer; 2017 May; 116(10):1247-1253. PubMed ID: 28350787
[TBL] [Abstract] [Full Text] [Related]
5. Targeting the NF-κB pathway in prostate cancer: a promising therapeutic approach?
Verzella D; Fischietti M; Capece D; Vecchiotti D; Del Vecchio F; Cicciarelli G; Mastroiaco V; Tessitore A; Alesse E; Zazzeroni F
Curr Drug Targets; 2016; 17(3):311-20. PubMed ID: 26343112
[TBL] [Abstract] [Full Text] [Related]
6. Assessment of rectal distention in radiotherapy of prostate cancer using daily megavoltage CT image guidance.
Engels B; Tournel K; Soete G; Storme G
Radiother Oncol; 2009 Mar; 90(3):377-81. PubMed ID: 19147247
[TBL] [Abstract] [Full Text] [Related]
7. Betulinic acid suppresses constitutive and TNFalpha-induced NF-kappaB activation and induces apoptosis in human prostate carcinoma PC-3 cells.
Rabi T; Shukla S; Gupta S
Mol Carcinog; 2008 Dec; 47(12):964-73. PubMed ID: 18444250
[TBL] [Abstract] [Full Text] [Related]
8. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer.
Caffo O; Fellin G; Bolner A; Coccarelli F; Divan C; Frisinghelli M; Mussari S; Ziglio F; Malossini G; Tomio L; Galligioni E
Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):31-7. PubMed ID: 16765529
[TBL] [Abstract] [Full Text] [Related]
9. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection.
Fan S; Gao M; Meng Q; Laterra JJ; Symons MH; Coniglio S; Pestell RG; Goldberg ID; Rosen EM
Oncogene; 2005 Mar; 24(10):1749-66. PubMed ID: 15688034
[TBL] [Abstract] [Full Text] [Related]
10. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes.
Shukla S; Gupta S
Clin Cancer Res; 2004 May; 10(9):3169-78. PubMed ID: 15131058
[TBL] [Abstract] [Full Text] [Related]
11. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma.
Santourlidis S; Warskulat U; Florl AR; Maas S; Pulte T; Fischer J; Müller W; Schulz WA
Mol Carcinog; 2001 Sep; 32(1):36-43. PubMed ID: 11568974
[TBL] [Abstract] [Full Text] [Related]
